Saturday 17 October 2026
Export CURX’s income statement to Excel — free account
Curanex Pharmaceuticals Inc
CURX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 4,671.4% and free cash flow fell 272.3%, each against the same quarter a year earlier.
4.62
0.21
−4.35%
Follow CURX
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
81.95 | 35.47 |
Net Debt/EBITDA |
1.20 | 0.41 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
2.48 | 1.54 |
Capex/Depreciation |
0.00 | — |
Interest Coverage |
(498.72) | — |
| (72.09%) | 0.00% | |
| (69.85%) | 0.00% | |
ROIC |
(42.42%) | (64.37%) |
Return on Tangible Assets |
(38.10%) | (71.83%) |
Research and Development Expense of Revenue |
0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Free Cash Flow per Share |
(8.22) | (0.84) |
Cash per Share |
3.90 | 0.22 |
Shareholders Equity per Share |
8.80 | 0.76 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
8.80 | 0.76 |
Free Cash Flow |
(10.48) | (0.56) |
Working Capital |
11.09 | 0.50 |
Net Current Asset Value |
10.87 | 0.50 |
| Other line items | ||
Quick Ratio |
36.30 | 10.20 |
Depreciation/Fixed assets |
0.00 | — |
Cash ROIC |
(64.75%) | (85.18%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(8.22) | (0.84) |
Capex per Share |
0.00 | 0.00 |
Average Payables |
0.00 | — |
Average Assets |
6.05 | — |
Average Common Equity |
5.86 | — |
Columns are period end dates